Biotech Values

[drbio45]

that means nothing ignore 84086

they do not mention response rates. The trial is how old?
you can relapse and still live for two years so that fact that they haven't had deaths doesn't mean much.

chemgenex has an 85 percent response rate in the t315i mutation trial and an 80 percent response rate in the trial that people have failed at least 2 tki's and 51 percent of the patients failed all three, and everyone poo-poohed the data.

Chemgenx filed their NDA and will be approve in the first quarter. then it becomes the standard of care. How will ariad be able to enroll an open label study even if the FDA lets them, if Omacetaxine becomes the standare of care early next year.